Lead vac­cine from Vi­cal and Astel­las flops in a Phase II her­pes study

San Diego-based Vi­cal $VI­CL says that its lead vac­cine ASP0113 flopped in a Phase II study de­signed to thwart her­pes in kid­ney trans­plant pa­tients. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA